Promoter polymorphisms of the BLyS gene and use in diagnostic methods
View Patent ↗The present invention provides an isolated polynucleotide comprising at least one polymorphic nucleotide sequence, for example, at position −871 from the promoter region of the BLyS gene, and diagnostic assays for detecting the presence of this polymorphism associated with a condition associated with BLyS activity, such as hematological malignancy including B cell malignancies. The diagnostic assays are useful in predicting an individual's likelihood of developing a condition associated with BLyS activity, such as hematological malignancies, and for methods for treating an individual clinically diagnosed with a condition associated with BLyS activity, such as prediction of a patient's likelihood to respond to a specific drug treatment. The invention also provides an array of nucleic acid molecules immobilized on a solid surface, where at least one of the nucleic acid molecules comprises a BLyS polymorphic nucleic acid molecule. The nucleic acid arrays of the invention allow rapid detection of hybridizing nucleic acid-molecules, in a nucleic acid sample from an individual, of a BLyS polymorphism associated with hematological malignancy.
1. A method of assessing the likelihood that a human will develop familial B chronic lymphocytic leukemia (B-CLL), wherein said method comprises:
(a) determining whether or not said human has a first or second degree relative diagnosed with a B-cell lymphoprolifative malignancy,
(b) analyzing a polynucleotide to determine whether or not said human comprises a polymorphism in a B-lymphocyte stimulator (BLyS) gene, wherein said polymorphism is a C to I transition 871 bases 3′ of the transcriptional start site of the BLyS gene, and
(c) classifying said human as being likely to develop said familial B-CLL if said human has said relative and said polymorphism.
2. The method of claim 1 , wherein said human has said relative and said polymorphism.
3. The method of claim 1 , wherein said determining step (b) comprises contacting a polynucleotide from said human with a polynucleotide probe which hybridizes to the polymorphism under stringent conditions and determining whether hybridization has occurred, thereby indicating the presence of the polymorphism.